FDA 483 - David M. Stoll, MD - May 09, 2011
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of David M. Stoll, M.D., a bioresearch clinical investigator in Santa Monica, CA, revealed significant deficiencies in the conduct of clinical investigations. Observations included failure to follow investigational plans, unauthorized changes to source records, inadequate IRB communication regarding protocol deviations and study termination, and issues with maintaining accurate case histories and informed consent documentation. These findings indicate a serious lack of oversight and adherence to regulatory requirements in clinical trial conduct.
ID · bae26865-7463-416c-80c0-f9217ae64d92